Could a common heart drug treat kaposi sarcoma?
NCT ID NCT05797662
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether propranolol, a drug usually used for high blood pressure, can treat Kaposi sarcoma. About 25 children and adults will take propranolol pills for up to 24 weeks. Researchers will measure how many participants see their tumors shrink or disappear, and track any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
propranolol
What this could lead to
If it works, this could offer a low-cost, well-tolerated treatment option for Kaposi sarcoma, potentially reducing the need for chemotherapy.
What could go wrong
This is a small, early-phase trial with only 25 participants and no comparison group. Propranolol may not shrink tumors effectively, and side effects like low blood pressure or fatigue are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
African Cancer Institute at Stellenbosch
Cape Town, South Africa
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Complexo Hospitalar Universitário Professor Edgard Santos
Salvador, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fundación Huésped
Buenos Aires, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Nacional de Cancerologia
Mexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Instituto Nacional de Câncer José de Alencar
Rio de Janeiro, 20231-050, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moi University School of Medicine
Eldoret, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UNC Project Malawi
Lilongwe, Malawi
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Uganda Cancer Institute
Kampala, Uganda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Zimbabwe College of Health Sciences
Harare, Zimbabwe
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••